MHRA

#Association of the British Pharmaceutical Industry #MHRA #Regulatory #UK

MHRA reveals 2030 Strategy to modernise patient-centred regulation

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2030 Strategy, setting out ambitious plans to translate scientific and technological innovation into better health outcomes.  The regulator says that the commitments will enable it to keep pace with rapid advances in science, technology and personalised… Read More

#News #Regulatory #Trending News

Weight loss tablets
#Eli Lilly #GLP-1 #MHRA #Obesity #Type 2 diabetes #Weight loss

UK first in Europe to authorise Lilly’s weight loss tablet orforglipron

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised orforglipron (Foundayo), making it the first country in Europe to approve the GLP-1 tablet for both weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorised for weight loss and… Read More

#News #Regulatory

Cardiovascular system
#Cardiovascular disease #Cytokinetics #MHRA #National Institute for Health and Care Excellence (NICE)

Myqorzo gets concurrent approvals from UK’s MHRA and NICE

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Myqorzo (aficamten) a marketing authorisation across the UK for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM).   At the same time, the National Institute for Health and Care Excellence (NICE)… Read More

#News #Regulatory

Doctor showing a model of the prostate
#Johnson & Johnson #MHRA #Prostate cancer #UK

Prostate cancer therapy gets MHRA marketing authorisation

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to a treatment for metastatic hormone-sensitive prostate cancer (mHSPC).  Akeega (niraparib and abiraterone acetate), developed by Johnson & Johnson, has been granted the authorisation as part of a combination regimen with prednisone or prednisolone and andogren deprivation therapy (ADT). … Read More

#News #Regulatory

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 30 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More

#Podcasts

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 23 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More

#Podcasts

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

#GLP-1 #MHRA #Obesity #UK #Weight loss

Wegovy pill could help patients lose 17% body weight 

The new Wegovy pill could help patients lose 17% of their body weight, clinical trial results show.  The tablet version of Wegovy, approved in the UK by MHRA, is the first GLP-1 weight-loss pill licensed for weight management in the UK and is expected to become available… Read More

#News

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

FDA headquarters
#Clinical trials #MHRA #Rare disease #Regulatory #SynaptixBio

UK should offer US-style incentives in rare diseases, says biotech

The UK Medicines & Healthcare Regulatory Agency (MHRA) is consulting on a new regulatory framework for bringing rare disease drugs more quickly to market.  The new Rare Disease Therapies Regulatory Framework is intended to “support earlier, more frequent, and iterative engagement with developers, providing structured regulatory flexibility… Read More

#News #Regulatory

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

#AI #Clinical trial #MHRA

First AI drug enters clinical development 

The first oral drug formulated by AI has been advanced into clinical development.  CRDMO Quotient Sciences has announced a Phase I study of the drug was initiated at the company’s UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA).   The study will… Read More

#News

MHRA
#Life sciences #MHRA #Northern Ireland

MHRA to open Northern Ireland hub to boost life sciences 

The Medicines and Healthcare products Regulatory Agency (MHRA) is opening a new hub in Northern Ireland to boost life sciences growth in the country.  The hub, hosted by Invest Northern Ireland, aims to build on MHRA’s partnerships in healthcare, academia and industry in… Read More

#News #Regulatory